Immunocore Holdings plc (NASDAQ:IMCR) Stock Position Raised by Wellington Management Group LLP

Wellington Management Group LLP boosted its position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 10.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 7,048,833 shares of the company's stock after acquiring an additional 668,382 shares during the period. Wellington Management Group LLP owned about 14.09% of Immunocore worth $219,430,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Exchange Traded Concepts LLC grew its stake in shares of Immunocore by 40.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company's stock valued at $158,000 after buying an additional 1,461 shares during the period. Connective Portfolio Management LLC purchased a new stake in shares of Immunocore during the 3rd quarter valued at $218,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Immunocore by 69.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company's stock valued at $231,000 after buying an additional 3,053 shares during the period. XTX Topco Ltd purchased a new stake in shares of Immunocore during the 2nd quarter valued at $303,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Immunocore during the 3rd quarter valued at $406,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Stock Up 1.0 %

Shares of Immunocore stock traded up $0.33 during trading on Monday, reaching $31.85. The company had a trading volume of 135,608 shares, compared to its average volume of 501,345. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -33.35 and a beta of 0.73. The firm's fifty day moving average is $32.30 and its 200-day moving average is $35.76. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. Immunocore Holdings plc has a fifty-two week low of $29.72 and a fifty-two week high of $76.98.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.50. The business had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company's revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.59) EPS. On average, analysts anticipate that Immunocore Holdings plc will post -0.94 EPS for the current year.

Wall Street Analysts Forecast Growth

IMCR has been the topic of several recent research reports. UBS Group initiated coverage on shares of Immunocore in a report on Thursday, October 24th. They set a "sell" rating and a $24.00 target price on the stock. Needham & Company LLC reduced their target price on shares of Immunocore from $78.00 to $71.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Morgan Stanley reduced their target price on shares of Immunocore from $80.00 to $74.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. HC Wainwright restated a "buy" rating and set a $100.00 target price on shares of Immunocore in a report on Thursday, October 24th. Finally, Guggenheim lowered shares of Immunocore from a "buy" rating to a "neutral" rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $69.18.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.